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The extraction of energy and biosynthetic building blocks from fuel metabolism is a fundamental requisite for life.
Through the action of cellular enzymes, complex carbon structures are broken down in reactions coupled to the
production of high-energy phosphates as in ATP and GTP as well as electron carriers such as NADH and FADH2.
These processes traverse across compartments inside the cell in order to access specific enzymes and
environments. Pyruvate is the end product of cytosolic glycolysis and has a variety of possible fates, the major one
being mitochondrial oxidation. While this metabolite has been known to cross the inner mitochondrial membrane
for decades, it is only recently that proteins necessary for this activity have been identified. This review will
chronicle more than 40 years of research interrogating this critical process and will discuss some of the possible
implications of this discovery for cancer metabolism.Review
An extensive body of work has accumulated over decades
on the subject of mitochondrial pyruvate transport. Since
the earliest proposition of a specific transporter for pyru-
vate in 1971 there has been continuous debate about its
existence and nature [1]. Updates to techniques measuring
pyruvate transport have led to revisions regarding kinetics,
the metabolites that modulate transport activity, and the
molecular sizes of the proposed transporter culminating
in the identification of a putative transporter [2]. Unfortu-
nately, this member of the mitochondrial carrier family
(MCF) was later demonstrated to be a NAD+ transporter,
whose activity resembled the pyruvate transporter in
in vitro assays due an effect on the NAD+ dependent
pyruvate dehydrogenase complex [3]. At the same time
clinicians studying metabolic diseases were frustrated by
mysterious cases of defective pyruvate metabolism, which
displayed normal pyruvate dehydrogenase (PDH) enzyme
activity and did not have mutations in any known compo-
nents of the pyruvate metabolic system [4]. The obvious
remaining candidate, the mitochondrial pyruvate carrier,
could not be sequenced for mutations because the gene or
genes encoding it had not been identified. In this review,
we will take a historical perspective to describe the fits* Correspondence: rutter@biochem.utah.edu
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distribution, and reproduction in any mediumand starts that recently culminated in the recent identifi-
cation of the long-sought mitochondrial pyruvate carrier
(MPC) [5,6].
Membrane transport
Membranes provide the cell with the essential ability to
delineate the unregulated external environment from the
specific and homeostatically controlled internal milieu.
Within the cell, compartments can be further subdivided
and therefore assigned specialized functions. This separ-
ation is essential for generating and utilizing electrical
potential via regulated ion current, protection of precious
replicative information from mutagenic insults, enforcing
colocalization of molecules, and conversion of high energy
electrons into high energy phosphates using proton flow.
The benefits of separable intracellular compartments are
only truly achieved when the transport of molecules across
membranes is regulated. This regulation occurs by a var-
iety of mechanisms, including but not limited to: post-
translational modifications, increased mRNA and protein
synthesis, altering transporter stability, and deploying
transporters stored in vesicles. Of particular relevance for
the present subject, the regulation of metabolite move-
ment and subsequent access to enzymes is a powerful and
commonly employed method for biological regulation.
While we often focus on the enzymes that act on metabo-
lites, we must not take for granted the fact that they must
first be given access to these enzymes.ntral Ltd. This is an Open Access article distributed under the terms of the
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what confusing nomenclature. The term ‘transporter’ is
commonly used to describe most proteins that facilitate
movement across a membrane but this can further be seg-
regated into carriers and channels. Channels are used to
conduct ions and cycle between open and closed states,
with some also exhibiting an inactivation step. They form
a completely continuous tunnel through a bilayer that
allows for rapid conductance of many ions. A carrier, in
contrast, does not form a complete pore but is open to
one side of the bilayer at a time and substances are trans-
ported during the cycling of these conformations. Chan-
nels are typically found in circumstances where large
amounts of ions must be rapidly conducted as in electrical
signaling while carriers are often utilized in situations
wherein capacity is less critical [7].
Pyruvate metabolism
Pyruvate is a key node in the branching pathways of glu-
cose, fatty acid and amino acid metabolism. The overall
metabolic profile of the cell dictates its metabolism, which
is highly dynamic to allow this molecule to be generated
and used when and where it is most needed. Perhaps the
most straightforward and quantitatively important source
of pyruvate is from the breakdown of carbohydrates suchFigure 1 Overview of cellular pyruvate movement and metabolism.as glucose through glycolysis. Glucose enters the cytosol
through specific transporters (the GLUT family) and is
processed by one of several pathways depending on cellu-
lar requirements. Glycolysis occurs in the cytosol and
produces a limited amount of ATP, but the end product is
two 3-carbon molecules of pyruvate, which can be diverted
yet again into many pathways depending on the require-
ments of the cell. In aerobic conditions, pyruvate is pri-
marily transported into the mitochondrial matrix and
converted to acetyl-coenzyme A (acetyl-CoA) and carbon
dioxide by the pyruvate dehydrogenase complex (PDC).
For access to the mitochondrial matrix, three layers must
be traversed: the outer mitochondrial membrane, the inter-
membrane space, and the inner mitochondrial membrane
(Figure 1). Most of the metabolic activities of mitochondria
occur in the matrix, either by soluble proteins or enzymes
embedded in the inner membrane.
Transport of pyruvate across the outer mitochondrial
membrane appears to be easily accomplished via large
non-selective channels such as voltage-dependent anion
channels/porin, which enable passive diffusion [8]. Indeed,
deficiencies in these channels have been suggested to
block pyruvate metabolism [9]. The movement through
the inner mitochondrial membrane is far more restrictive,
however. The tight control over matrix accessibility makes
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of mitochondrial metabolic enzymes are localized. Many
metabolites have specific mitochondrial inner membrane
transporters that have been identified and well studied [10].
Once within the mitochondrial matrix, pyruvate may be
diverted into two disparate paths. On one path pyruvate is
carboxylated to form oxaloacetate, which can be used for
gluconeogenesis. On the other path, pyruvate is decar-
boxylated to form Acetyl-CoA. After conversion to acetyl-
CoA in the mitochondrial matrix, pyruvate’s potential fates
are constrained. While components of the tricarboxylic
acid (TCA) cycle may be used to produce amino acids,
fatty acids, or glucose, the carbons from pyruvate are pri-
marily converted to carbon dioxide. In the process, the en-
ergy from pyruvate is converted into high energy reducing
intermediates that power the electron transport chain.
Due to the impact of this decision, the choice to convert
pyruvate into acetyl-CoA is tightly regulated [11].
In oxygen-depleted environments, cytosolic pyruvate is
converted into lactate and exported from the cell in a
process known as anaerobic glycolysis. Without the requis-
ite oxygen necessary to oxidize the pyruvate carbons, the
cell is required to generate energy via this method. Certain
cell types also engage in a form of glucose metabolism
known as aerobic glycolysis in which glycolysis-derived
pyruvate is converted to lactate even when oxygen is ad-
equate for pyruvate oxidation. This seemingly wasteful
decision is a common component of the metabolic altera-
tions in a variety of cancers. No discussion of cancer me-
tabolism, especially one focusing on pyruvate, would be
complete without a reference to Otto Warburg and his ob-
servation that tumor cells utilize aerobic glycolysis, subse-
quently named the ‘Warburg effect’ [12]. Currently there is
intense interest in understanding what role the Warburg
effect plays in cancer initiation and growth, with therapeu-
tics being developed in the hope of reversing metabolic
changes required by the cancer cells [13,14]. This work is
enabled by our rather sophisticated understanding of many
aspects of central carbon metabolism and its regulation.
One question of fundamental importance has remained,
however: how does pyruvate move across the inner mito-
chondrial membrane?
The problem
In diagrams of metabolism, the canonical depiction of
pyruvate transport into the mitochondria is a solid arrow
traversing the mitochondrial inner membrane. Initially it
was proposed that pyruvate was able to cross the mem-
brane in its undissociated (acid) form but evaluation of
its biochemical properties show that it is largely in its
ionic form within the cell and should therefore require a
transporter [15,16]. While a minor detail to most, the
solid arrows traversing membranes are a source of frus-
tration to those that seek to understand how substratepartitioning can influence metabolic decisions. Although
much remains unknown, two independent studies have
rigorously tested two mitochondrial inner membrane
proteins [5,6]. Originally named BRP44L and BRP44
(now named MPC1 and MPC2, respectively), these pro-
teins have been shown to form a complex that is neces-
sary and sufficient for the movement of pyruvate across
the mitochondrial inner membrane and into the matrix.
Decades of research have investigated the mitochondrial
pyruvate carrier (MPC), all without knowing the encoding
gene or genes. These studies range from observational in-
quiries in general or specific situations to intensive and fo-
cused studies on the kinetics and biochemistry of the
MPC. In spite of the challenge of not knowing the genes
or structure, these pioneering scientists generated an ex-
tensive base of knowledge regarding the mitochondrial
pyruvate carrier and its functional characteristics. Due to
space considerations, we are only able to comment on a
few of the elegant studies conducted by a number of rigor-
ous scientists over decades of endeavor.
Prior studies of mitochondrial pyruvate transport
Diffusion across the membrane or transport?
Like many fields of study, the mitochondrial pyruvate car-
rier has been the subject of significant disagreement over
the last 40 years. In spite of the controversies, these stud-
ies have enhanced the understanding of the MPC and
have honed the techniques for its analysis. The earliest as-
sumption of pyruvate movement was that it could traverse
the inner membrane in its undissociated form despite the
acknowledgement that the inner membrane was a select-
ive barrier for the movement of other metabolites [15].
Using protein-free liposomes it was found that pyruvate
did indeed have the ability to cross membranes directly
[17]. A potential caveat of these studies was the use of
100 mM pyruvate, a concentration that is roughly 1,000-
fold higher than would is typically encountered within the
cell [18,19]. In addition, artificial membranes used in these
studies may not replicate the permeability and other prop-
erties of the mitochondrial inner membrane. Indeed, later
studies unequivocally demonstrated transporter-mediated
pyruvate movement.
The interest in the mitochondria and metabolite trans-
porters extended to pyruvate movement and in 1971 Papa
et al. provided evidence that pyruvate moved across the
mitochondrial membrane via a specific translocator and is
coupled to ion exchange [1]. In this study the authors
purified mitochondria from rat liver and preincubated the
suspension with inhibitors to block pyruvate metabolism
and inhibit the electron transport chain and subsequent
ATP production. Radiolabeled pyruvate was then added to
the mitochondria and the mixture was centrifuged either
directly or through a silicone oil differential gradient into
HClO4 to control the kinetics of the reaction and stop
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translocation and exchange displayed saturation kinetics,
which they argued established the existence of a specific
pyruvate transporter. The data provided by this work was
also the first suggestion that pyruvate movement across
the inner mitochondrial membrane was coupled to a pro-
ton gradient. This coupling to the proton gradient was
rationalized as a positive feedback loop to supply active,
energetically coupled and respiring mitochondria with
additional fuel.
This initial suggestion of a mitochondrial pyruvate car-
rier was countered by a report that pyruvate adsorption to
the membrane and not transport across it was responsible
for the findings [20]. The contrary conclusions were par-
tially based on the finding that boiled and denatured mito-
chondria accumulate pyruvate to a similar level as active
mitochondria in a pH-dependent manner. While this
study provides an alternative mechanistic explanation for
the in vitro observations, their findings did not preclude
the existence of a carrier. Nevertheless, this paper pre-
sented a challenge that would need to be answered in
order to justify continued study of the putative MPC.
Identification of specific inhibitors
Shortly after this report a key advance was made that so-
lidified the argument for a specific transporter. Halestrap
and colleagues identified and characterized an inhibitor of
mitochondrial pyruvate transport. α-Cyano-4-hydroxycin-
namate (CHC) was observed to inhibit pyruvate oxidation
and found to do this by blocking mitochondrial pyruvate
transport. In whole mitochondria, the inhibitor blocks
transport and therefore metabolism but the inhibitor has
no effect on ruptured mitochondria [21]. In this way it is
possible to ascribe the inhibitory effect to be at the mem-
brane rather than a mitochondrial enzyme. CHC and other
cinnamate-based inhibitors resemble the enol form of
pyruvate with an attached aromatic ring [22]. In the ab-
sence of reverse genetics, chemical modulation was the
only available methodology to perturb protein function
and measure the effects. The lack of an inhibitor had been
a major basis for the earlier claim that a specific mitochon-
drial pyruvate carrier did not exist [15]. With an inhibitor,
the properties of the carrier could be investigated more
rigorously and separated from diffusion through the mem-
brane, adsorption or the activity of other transporters.
Inhibitor-stop technique and modulation by other
metabolites
The discovery of an inhibitor enabled the use of the
‘inhibitor-stop’ technique to carry out detailed biochemical
studies on the carrier [23]. This technique had been used
to characterize the transport of other metabolites and
allows metabolite exchange for a specified time followed
by introduction of the inhibitor to stop the transportreaction and rapid sedimentation of the mitochondria.
Beyond this specific inhibitor, the effect of other metabo-
lites on pyruvate uptake and oxidation was investigated.
Almost simultaneous studies showed the inhibitory effects
on pyruvate transport of α-ketoacids and phenylpyruvate,
lending additional physiological validity to the presence of a
transporter [24,25]. These observations relate to the first
implication of the mitochondrial pyruvate carrier in human
disease. Specifically, toxic accumulation of phenylpyruvate
in phenylketonuria patients could disrupt oxidative metab-
olism by preventing normal pyruvate movement into the
mitochondria [25,26]. Malate, an intermediate in the citric
acid cycle, was shown to significantly increase mitochon-
drial uptake of pyruvate while not affecting affinity. The ini-
tial characterization of the kinetics of pyruvate transport
showed that it appeared to follow first-order kinetics and
have a higher rate constant than mitochondrial succinate
or citrate transport [24]. As the rate of transport across a
membrane is notoriously difficult to determine, later stud-
ies would revise these values.
Expanding upon the discovery of cinnamates as MPC
inhibitors, it was shown that these compounds also inhibit
the transport of pyruvate across the plasma membrane of
erythrocytes, but they do so much less potently, suggesting
that the two membranes have different transporters [27].
This study also implicated the MPC in gluconeogenesis.
Because pyruvate must be converted to oxaloacetate in the
mitochondria and exported to the cytosol for conversion
to glucose, inhibition of gluconeogenesis is completely
expected. Utilizing the knowledge that the plasma mem-
brane pyruvate transporter in erythrocytes is less sensitive
to the inhibitors it was possible to use a concentration that
would only prevent mitochondrial transport and show that
this lower concentration had a similar effect on gluconeo-
genesis, once again implicating the mitochondria as a me-
diator of this essential process [21].
Using an altered definition for pyruvate transport that
was limited to what could be blocked by the inhibitor,
Pande and Parvin provided new data for the inhibition of
the transporter by cinnamates [28]. Even after CHC-
treated mitochondria were washed with 60 mM pyruvate,
concentrations of pyruvate that would normally drive
pyruvate oxidation (1 mM) failed to do so, suggesting the
mechanism of inhibition is non-competitive. The same
study also showed that respiration experiments in the
presence of 60 mM pyruvate became insensitive to CHC.
Therefore, while CHC doesn’t appear to be a competitive
inhibitor, high concentrations of pyruvate (60 mM) can
overcome inhibition of transport. These authors attributed
this phenomenon to a carrier-independent and inhibitor-
insensitive method of pyruvate movement into the mito-
chondria. Distinction of carrier-dependent and independent
pyruvate movement is a notable advance necessary for
developing experimental systems to investigate pyruvate
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also represents a key physiological basis for the necessity of
a specific transporter. At the low physiological concentra-
tions of pyruvate found within the cytosol, diffusion would
be unable to adequately transport this essential metabolite
to its site of metabolism in the matrix.
Pyruvate transport as a rate-limiting step in pyruvate
oxidation
Further studies of the kinetics of pyruvate uptake found
the rate to be quite low (Vmax = 0.54 ± 0.03 nmol per mi-
nute per mg of mitochondrial protein) compared to other
transport systems [29]. By analogy with glutamate trans-
port, which is also rather sluggish and thought to be the
rate-limiting step in glutamine metabolism, this raised the
possibility that mitochondrial pyruvate transport might be
rate limiting for pathways requiring mitochondrial pyru-
vate, like oxidation and gluconeogenesis [30]. Data in favor
of rate-limiting control for the MPC later came from
Pande and Parvin [28]. Using the revised method for de-
termining pyruvate uptake described above, they deter-
mined even slower rates for MPC activity. This technique
and accompanying paper questioned much of the previous
work on the transporter. The rate limitation of pyruvate
uptake on oxygen consumption in the presence of ADP
was later confirmed [31].
At this point, many important questions regarding the
properties of the pyruvate transporter remained problem-
atic. Various studies were providing contradictory conclu-
sions regarding metabolite effects on pyruvate transport
[25,28,29,32]. Providing definitive answers surrounding the
phenomenon of mitochondrial pyruvate transport would
require the identity of the genes and proteins involved to
allow biochemical purification and reconstitution in an iso-
lated system. Studying transport properties in the context
of the mitochondrial membrane is extremely difficult due
to the presence of other transporters and ongoing metabol-
ism. The purification, identification and reconstitution of
the transporter would solve many of these issues. As a re-
sult, great effort was expended to accomplish these goals.
Purification
Purification of the transporter and reconstitution into
liposomes would provide the single best system for char-
acterizing transport properties as well as sharpening the
focus onto this one activity. Such an isolated system is per-
haps the highest threshold to be achieved in biochemical
studies and is one of the most difficult enterprises to
undertake, made even more difficult by the lack of identity
of the proteins. Without knowing their identity, overex-
pressing and tagging of the proteins for purification would
not be possible. In spite of the challenges, the purification
and reconstitution of pyruvate transport activity from mito-
chondria was demonstrated in 1986 [33,34]. Specifically,pyruvate exchange activity across proteoliposomal mem-
branes was studied and shown to be sensitive to 2-cyano-4-
hydroxycinnamate. While this represented a critical step in
the studies of mitochondrial pyruvate transport, the MPC
was not purified. Attempts to reconstitute a purified prep-
aration of the MPC were first described in castor bean
mitochondria [34]. When subjected to SDS-PAGE, the ac-
tive, partially purified mixture contained proteins of 74, 66,
34, 32, 30 and 12 kDa. These data led the authors to con-
clude that one or more of the proteins was the pyruvate
transporter, but complete purification remained elusive.
New strategies would likely be required to achieve this goal.
Two papers in 1984 and 1986 described the binding
properties of the MPC for α-cyanocinnamate [35,36]. Stud-
ies using a 14C labeled inhibitor provided information on
binding and dissociation beyond what could be learned
from activity measurements. Using this system, the authors
drew several parallels between inhibitor binding and inhib-
ition of pyruvate transport, thus providing support for a
direct relationship between the inhibitor, the MPC and
pyruvate transport [35]. Additionally, preincubation of
mitochondria with UK5099 for 30 minutes caused stable
MPC inhibition that was not reversed by subsequent 100-
fold dilution (while control experiments showed that
NADH and succinate metabolism was preserved) [34]. The
data supporting a stable inhibitor-bound complex led to
the idea of using an immobilized inhibitor as a means of
purifying the MPC.
The Azzi group that had previously reconstituted pyru-
vate transport activity using hydoxyapatite chromatog-
raphy refined their methods in an attempt to identify the
specific proteins involved. For these studies they covalently
immobilized the inhibitor 2-cyano-4-hydroxycinnamate
on sepharose. Following one-step hydroxyapatite purifica-
tion, the mitochondrial fraction was passed through the
cinnamate column. Both 34 kDa and 31.5 kDa proteins
were observed following elution [37]. We currently have
no way to explain the molecular weights of the proteins
found in this study in light of the smaller size of the newly
discovered MPC proteins, but it is possible that the
observed proteins were monocarboxylate (MCT) trans-
porters, which are predominantly at the plasma mem-
brane, but have been proposed to exist in mitochondria
[38]. The authors did find that higher concentrations of
inhibitor were required to block transport activity com-
pared to isolated intact mitochondria and Halestrap previ-
ously showed that this is the case for the MCT pyruvate
transporter compared to the mitochondrial carrier. These
initial studies in bovine heart were followed by similar
work in rat liver with similar results showing proteins in
the 29 to 37 kDa size range catalyzing pyruvate transport
[39]. Now with the identification of the MPC it will be
possible to go back and re-evaluate these studies. The
MCTs may also represent another mode of pyruvate
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centrations although there is no definitive data on this.
Similar studies in Saccharomyces cerevisiae identified two
polypeptides with a molecular mass of 26 kDa and
50 kDa, failing to purify the 34 kDa protein identified as
the transporter in bovine heart. In addition to the size dis-
crepancy, it was found that their activities were different,
with the yeast carrier being more active but less abundant
than what was purified and reconstituted from bovine and
rat tissue [40].
Fits and starts toward identification
α-Cyanocinnamate was shown to protect the pyruvate
transporter from the thiol-blocking reagent N-phenylma-
leimide and diminished labeling of a 15 kDa protein by
radiolabeled N-phenylmaleimide in rat liver and heart
mitochondria. This experiment also revealed a 12 kDa
protein in heart mitochondria that was not detected in
liver leading the authors to conclude it was most likely a
proteolytic breakdown product [41]. Unfortunately, the
same authors later found that the 15 kDa protein was a
subunit of cytochrome oxidase (COXIV) [2].
Even with these purification procedures in hand, the
identity of the transporter remained a mystery. From what
had been uncovered regarding mitochondrial transport of
other metabolites, it seemed likely that pyruvate transport
would be facilitated by a member of the mitochondrial
carrier family (MCF) [42]. In 2003, a report was published
claiming to have finally identified the mitochondrial pyru-
vate carrier [2]. Using S. cerevesiae, the authors focused
specifically on the MCF protein family, comprised of 35
proteins in yeast. In total, 16 had been previously charac-
terized and had known substrates. Of the remaining
proteins, 1 was essential for growth under respiratory con-
ditions, which left 18 to characterize. A systematic analysis
of strains individually lacking each of the 18 MCF proteins
produced 1 candidate, the 41.9 kDa protein encoded by
YIL006w. This mutant displayed the lowest level of pyru-
vate uptake and weakest response to UK5099, but had
limited conservation from yeast to Drosophila, mouse,
and man. Unfortunately, 3 years later it was found that
this protein likely functions to transport NAD+ into the
mitochondrial matrix, which was definitively proven by
liposomal reconstitution [3]. Indeed, phylogenetic analysis
showed a clustering of this MCF protein with other nu-
cleotide transporters. The alterations in ‘pyruvate trans-
port’ originally observed were likely a result of reduced
activity of the NAD+-requiring pyruvate dehydrogenase
complex. This technique was used to characterize other
MCF proteins but failed to identify the MPC [43].
The approach employed by Hilyard et al. highlights the
potential pitfalls and difficulty of searching for protein
functions using family characteristics and sequence hom-
ology. It cannot, however, be understated how difficultthese transporter studies were, especially with unidentified
proteins. Characterizing basic biochemical attributes of
membrane proteins is difficult and tedious work and
achieving reproducible results requires zealous oversight.
The work done over several decades by Halestrap, Palmieri,
Papa, Azzi and their colleagues and many others represents
an incredible body of work that facilitated the identification
of the MPC.
Identification of the mitochondrial pyruvate carrier
Following these two papers, one claiming to have identi-
fied the mitochondrial pyruvate carrier and the second
calling this into question, studies on the carrier slowed.
Those that were carried out became increasingly focused:
pyruvate transport in frog mitochondria and cinnamate-
resistant sake yeast [44,45]. The eventual identification of
the MPC came from two groups, neither one of which
had set out to identify the carrier. Bricker et al. began with
highly conserved mitochondrial proteins with the logic
that sequence conservation was an indicator of essential
function [5]. Genetic ablation of the MPC genes in yeast
and flies led to an increase in glycolytic intermediates and
pyruvate with reductions in acetyl-CoA and TCA cycle
metabolites. Herzig et al. came upon the MPC by follow-
ing a defect in the synthesis in lipoic acid and growth
defects in the absence of valine and leucine [6]. These two
different approaches and very different experimental strat-
egies led to the same conclusion: the proteins under inves-
tigation assemble to form the elusive MPC.
The proteins found to be required for pyruvate trans-
port are quite small. Bricker et al. showed the proteins
were roughly 15 kDa by SDS PAGE and interacted to
form a larger complex consistent with some of the earlier
studies conducted by Brailsford et al. and Halestrap et al.
[34,41]. The MPC inhibitor UK5099 was used differently
by the two groups, but the data generated was comple-
mentary in establishing the necessity and sufficiency of
the MPC proteins for mitochondrial pyruvate uptake.
Bricker et al. used yeast genetics to identify a mutation of
MPC1 that conferred UK5099 resistance for growth and
in vitro mitochondrial pyruvate uptake. Herzig et al. estab-
lished the sufficiency of the MPC for mitochondrial pyru-
vate uptake. They expressed murine MPC1 and MPC2 in
Lactococcus lactis and showed that the two genes could
confer pyruvate uptake, but neither gene alone had any ef-
fect. They also showed that this reconstituted MPC was
sensitive to UK5099.
Bricker et al. also identified two point mutations in
human MPC1 that cause a metabolic syndrome that is
highly reminiscent of known defects in pyruvate metab-
olism [4]. Sequencing revealed two mutations in highly
conserved regions of MPC1 and metabolic studies
showed that the defect in pyruvate metabolism could be
rescued by expression of wild-type MPC1. These data
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MPC1/MPC2 complex is the major mitochondrial pyru-
vate transporter [46].
Implications of the discovery of the MPC genes
Despite the hidden identity of the mitochondrial pyruvate
carrier, many studies have provided important information
about the physiological significance and regulation of this
process. These studies touch on the relationship with glu-
coneogenesis, MPC control by hormones and drugs and
include relevance to pathological conditions including
hyperthyroidism, aging, and diabetes [47-55]. The clinical
relationship has also been investigated with respect to in-
born errors of metabolism. As expected, a defect in mito-
chondrial pyruvate transport causes a phenotype that is
similar to a mutation in one of the components of the
pyruvate dehydrogenase complex [4,5]. Now that the
MPC genes have been identified, we are now in a position
to determine whether patients that appear to have a PDH
mutation but retain normal enzymatic activity have a mu-
tation in one of these genes. As the epidemiology of PDH
mutations remains unknown it is difficult to estimate how
many potential idiopathic pyruvate metabolism defects
with normal PDH activity, of which there are many, may
be due to mutations of MPC [56].
Apart from basic metabolic disorders, the MPC may also
exert a significant pathophysiological effect on the meta-
bolic alterations found in cancer. At the most simplistic
level, the Warburg effect could be described as a loss or de-
crease of MPC function. Many other well-written reviews
have discussed cancer metabolism in depth so we will at-
tempt to focus on aspects with relevant to mitochondrial
pyruvate transport [57,58]. The study of metabolism in
cancer has expanded significantly with many studies exam-
ining the role of glycolysis, oxidative phosphorylation, fatty
acid oxidation, the TCA cycle, and hypoxia but previous
studies have not been able to provide models that integrate
mitochondrial pyruvate transport [59-61].
The limited work on mitochondrial pyruvate transport
in cancer has supported the expectation that changes in
the MPC may promote the glycolytic metabolic profile.
One early study found that the activity of the mitochon-
drial pyruvate transporter was an order of magnitude
lower in Ehrlich tumor cells compared to normal liver
cells implicating the MPC in the metabolic phenotype of
these cells [62]. A follow-up study comparing Ehrlich as-
cites, Morris hepatoma 44, and Morris hepatoma 3924A
cells with normal rat liver cells found that the Vmax of
the transporter was decreased and pyruvate supported
respiration was similarly reduced in each of the cancer
cell preparations. There were no significant changes in
transmembrane pH gradient, which may have explained
reduced transport activity. The authors concluded the
defect was due to lower transporter activity due to eithera reduction in the abundance of the carrier or due to
alterations in the cellular environment that may affect
the transporter [63]. In both the Morris hepatoma 44
and Morris hepatoma 3924A cells, the KM for pyruvate
transport was increased, implying that the MPC might
actually be different in those cells and exhibit a lower af-
finity for pyruvate.
Despite the limited data available on the connection be-
tween mitochondrial pyruvate transport and cancer me-
tabolism, the possible relationships and their implications
are exciting. The proximity of the MPC to metabolic
enzymes with a validated role in cancer metabolism draws
immediate attention to the MPC and its modulation in
cancer. Lactate dehydrogenase, the M2 isoform of pyru-
vate kinase, and pyruvate dehydrogenase act directly on
pyruvate metabolism and could indirectly affect its move-
ment into mitochondria [64-66]. Each of these enzymes is
altered in cancers, thereby perturbing pyruvate metabol-
ism. We therefore consider it reasonable to anticipate a
role for the MPC in cancer-relevant control of pyruvate
metabolism. Many outstanding issues regarding how the
MPC may contribute to the Warburg effect remain to be
addressed, including how these various enzymes and their
regulation interact in the context of cancer metabolism.
For example, reduced MPC expression or activity in the
face of altered cytosolic pyruvate metabolism, namely
through increased pyruvate kinase isozyme M2 (PKM2)
and lactate dehydrogenase (LDH), might provide only a
marginal exacerbation of the Warburg effect. In contrast,
reducing MPC in cancers with preserved cytosolic pyru-
vate metabolism might profoundly increase lactate pro-
duction and the manifestation of the Warburg effect.
There are many avenues of investigation available now
with the identification of proteins necessary for the mito-
chondrial import of pyruvate. Understanding how the
MPC fits into the complex environment of cancer metab-
olism sits at the forefront.
Conclusions
The metabolic profile of cancer has recently come back into
vogue with people espousing the century-old contributions
of biochemists, most notably Otto Warburg. Many sophis-
ticated studies in the past few years have placed cancer me-
tabolism in a deserved position of prominence in the field
of oncology. The initial observation that tumor cells pro-
duce high levels of lactate despite adequate oxygenation
was essential for future investigations of the mechanisms
and physiological importance of the Warburg effect. Key
tumor suppressors have been shown to regulate metabol-
ism and by doing so alter the fate of the cell. By controlling
the mitochondrial flow of pyruvate, a cancer cell can tune
its biology to meet the demands of rapid growth. Now with
the identification of the mitochondrial pyruvate carrier we
are poised to add yet another integral piece to this story
Schell and Rutter Cancer & Metabolism 2013, 1:6 Page 8 of 9
http://www.cancerandmetabolism.com/content/1/1/6and in doing so hopefully gain a better understanding that
will ultimately translate into therapy.
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